KORU Medical Systems, Inc. (then Repro Med Systems, Inc.) — Q1 2018 Form 10-Q
Reporting period: Three months ended March 31, 2018; filed May 7, 2018. The filing identifies the registrant as Repro Med Systems, Inc. The company designs, manufactures, and markets medical devices, primarily for ambulatory infusion and emergency medical applications.
Financial performance and position
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Net sales | $4.03 million | $3.64 million |
| Gross profit / margin | $2.47 million / 61.1% | $2.10 million / 57.8% per MD&A table |
| Operating profit | $501,129 | $206,059 |
| Net income | $403,427 | $126,951 |
| Net income per share, basic and diluted | $0.01 | Less than $0.01 as presented |
| Net cash from operating activities | $(13,114) | $143,446 |
| Cash and cash equivalents at period-end | $4.03 million | $3.46 million |
- Sales grew 10.9%, driven mainly by higher domestic needle-set volume; domestic sales rose 12.7% and international sales 2.3%.
- Gross profit increased 17.3%. Management attributed improved margins to sales growth, reduced scrap from nondestructive testing, and lower sterilization costs from consolidated loads.
- SG&A increased 5.9% to $1.88 million, while R&D fell to $9,848 from $45,906, partly due to attrition. Management said it hired an engineer in April 2018.
- Operating cash flow was slightly negative despite higher earnings, principally reflecting inventory build and payment of previously accrued bonuses, commissions, and severance. Investing activities provided $71,733, mainly from a certificate-of-deposit maturity; financing activities were nil.
- At March 31, current assets were $8.05 million and current liabilities $1.22 million, with working capital of approximately $6.83 million. The balance sheet reports no debt; total liabilities were $1.24 million.
Material changes, outlook, and risks
- Management anticipates 2018 growth in needle-set sales and organic growth, citing the updated Super 26g High Flo administration set and expanded FDA clearance for the FREEDOM System, including use with Cuvitru, Hizentra, and intravenous antibiotics. It also described potential additional applications, but gave no numerical guidance.
- The company said cash on hand and expected operating cash generation should fund operations, R&D, and capital expenditures for the next 12 months. It expects the subcutaneous immunoglobulin market to continue growing domestically and internationally.
- EMED Technologies litigation remains a material contingency, with unspecified damages and potential business impact. After quarter-end, the Federal Circuit affirmed a patent-review decision largely invalidating EMED’s ’476 patent on April 3; EMED sought en banc rehearing on April 18. EMED also filed a new antitrust, defamation, and unfair-business-practices case on April 23. Other patent proceedings and motions remained pending. The company cautioned that outcomes cannot be predicted and an adverse result could materially affect its business, results, financial condition, and cash flows.
- Management identified risks including FDA and other regulation, product demand and competition, market penetration, reimbursement, patent rights, R&D success, capital availability, key-personnel dependence, and litigation. It reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
- The company adopted the revenue-recognition standard effective January 1, 2018; it reported no material impact. It was assessing the effects of forthcoming credit-loss and lease-accounting standards.
- Stock repurchases were paused for an undetermined period to preserve cash for business expansion. The company reported 1.038 million outstanding stock options and 38.05 million common shares outstanding as of May 7, 2018, excluding treasury shares.
Important facts for investors to verify
- Reconcile the gross-margin comparison: the filing reports 61.1% for Q1 2018, while the prior-period figure appears as 57.8% in the MD&A table and 57.7% in the overview.
- Track whether sales growth and improved margins continue, and whether inventory investment converts into operating cash flow.
- Review updates and potential financial consequences of the EMED cases, including the post-quarter filings and pending court and patent-review actions.
- Assess whether the company’s 12-month liquidity expectation remains supported by cash generation, planned capital investment, legal costs, and operating needs.